NDAORALSUSPENSION, EXTENDED RELEASE
Approved
Dec 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
CLONIDINE (clonidine) by Gen Pharmaceuticals is clinical pharmacology clonidine stimulates alpha-adrenoreceptors in the brain stem. First approved in 2009.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Clonidine is an oral extended-release alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, lowering blood pressure, heart rate, and peripheral resistance. It is primarily used for hypertension management and acts relatively rapidly, with peak effect within 2-4 hours of oral dosing. The drug maintains stable hemodynamics over long-term therapy with intact postural reflexes.
$33MPart D
LOE ApproachingProduct approaching loss of exclusivity with moderate Part D utilization; brand team likely focused on retention and formulation differentiation strategies rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY Clonidine stimulates alpha-adrenoreceptors in the brain stem. This action results in reduced sympathetic outflow from the central nervous system and in decreases in peripheral resistance, renal vascular resistance, heart rate, and blood pressure. Clonidine hydrochloride…
Worked on CLONIDINE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.